메뉴 건너뛰기




Volumn 25, Issue 6, 2011, Pages 1189-1213

Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions

Author keywords

Acute myeloid leukemia; Consolidation; Induction; Postremission therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CLOFARABINE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; FLUDARABINE; FLURDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; IDARUBICIN; INTERLEUKIN 2; ISOCITRATE DEHYDROGENASE; LAROMUSTINE; LENALIDOMIDE; MIDOSTAURIN; MITOXANTRONE; MYELOBLASTIN; NUCLEOPHOSMIN; TIOGUANINE; TIPIFARNIB; TOPOTECAN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR;

EID: 81255177097     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.09.007     Document Type: Review
Times cited : (4)

References (136)
  • 1
    • 79958043675 scopus 로고    scopus 로고
    • National Cancer Institute, Bethesda (MD), Available at:, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Accessed September 29, 2011
    • Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review, 1975-2008 2010, National Cancer Institute, Bethesda (MD), Available at:, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Accessed September 29, 2011. http://seer.cancer.gov/csr/1975_2008/.
    • (2010) SEER cancer statistics review, 1975-2008
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3
  • 2
    • 33751267902 scopus 로고    scopus 로고
    • Acute myeloid leukaemia
    • Estey E., Döhner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
    • (2006) Lancet , vol.368 , pp. 1894-1907
    • Estey, E.1    Döhner, H.2
  • 3
    • 11944275668 scopus 로고
    • Etoposide in acute nonlymphocytic leukemia: Australian Leukemia Study Group
    • Bishop J.F., Lowenthal R.M., Joshua D., et al. Etoposide in acute nonlymphocytic leukemia: Australian Leukemia Study Group. Blood 1990, 75:27-32.
    • (1990) Blood , vol.75 , pp. 27-32
    • Bishop, J.F.1    Lowenthal, R.M.2    Joshua, D.3
  • 4
    • 59449093371 scopus 로고    scopus 로고
    • Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
    • Sekeres M.A., Elson P., Kalaycio M.E., et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009, 113:28-36.
    • (2009) Blood , vol.113 , pp. 28-36
    • Sekeres, M.A.1    Elson, P.2    Kalaycio, M.E.3
  • 5
    • 0026650021 scopus 로고
    • A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study
    • Vogler W.R., Velez-Garcia E., Weiner R.S., et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992, 10:1103-1111.
    • (1992) J Clin Oncol , vol.10 , pp. 1103-1111
    • Vogler, W.R.1    Velez-Garcia, E.2    Weiner, R.S.3
  • 6
    • 0026586008 scopus 로고
    • Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
    • Wiernik P.H., Banks P.L.C., Case D.C., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992, 79:313-319.
    • (1992) Blood , vol.79 , pp. 313-319
    • Wiernik, P.H.1    Banks, P.L.C.2    Case, D.C.3
  • 7
    • 0025907179 scopus 로고
    • Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
    • Berman E., Heller G., Santorsa J., et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991, 77:1666-1674.
    • (1991) Blood , vol.77 , pp. 1666-1674
    • Berman, E.1    Heller, G.2    Santorsa, J.3
  • 8
    • 0025275742 scopus 로고
    • Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)
    • Arlin Z., Case D.C., Moore J., et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990, 4:177-183.
    • (1990) Leukemia , vol.4 , pp. 177-183
    • Arlin, Z.1    Case, D.C.2    Moore, J.3
  • 9
    • 73949125089 scopus 로고    scopus 로고
    • Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid Leukemia: the EORTC and Gimema groups study AML-10
    • Mandelli F., Vignetti M., Suciu S., et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid Leukemia: the EORTC and Gimema groups study AML-10. J Clin Oncol 2009, 27:5397-5403.
    • (2009) J Clin Oncol , vol.27 , pp. 5397-5403
    • Mandelli, F.1    Vignetti, M.2    Suciu, S.3
  • 10
    • 70349467775 scopus 로고    scopus 로고
    • Anthracycline dose intensification in acute myeloid leukemia
    • Fernandez H., Sun Z., Yao X., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361:1249-1259.
    • (2009) N Engl J Med , vol.361 , pp. 1249-1259
    • Fernandez, H.1    Sun, Z.2    Yao, X.3
  • 11
    • 77649202987 scopus 로고    scopus 로고
    • Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study
    • Pautas C., Merabet F., Thomas X., et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010, 28:808-814.
    • (2010) J Clin Oncol , vol.28 , pp. 808-814
    • Pautas, C.1    Merabet, F.2    Thomas, X.3
  • 12
    • 79952122979 scopus 로고    scopus 로고
    • Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute leukemia: the JALSG AML201 study
    • Ohtake S., Miyawaki S., Fujita H., et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute leukemia: the JALSG AML201 study. Blood 2011, 117:2358-2365.
    • (2011) Blood , vol.117 , pp. 2358-2365
    • Ohtake, S.1    Miyawaki, S.2    Fujita, H.3
  • 13
    • 10244249096 scopus 로고    scopus 로고
    • A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
    • Weick J.K., Kopecky K.J., Appelbaum F.R., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996, 88:2841-2851.
    • (1996) Blood , vol.88 , pp. 2841-2851
    • Weick, J.K.1    Kopecky, K.J.2    Appelbaum, F.R.3
  • 14
    • 9044228414 scopus 로고    scopus 로고
    • Randomized study of high-dose cytarabine in induction in acute myeloid leukemia
    • Bishop J.F., Matthews J.P., Young G.A., et al. Randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
    • (1996) Blood , vol.87 , pp. 1710-1717
    • Bishop, J.F.1    Matthews, J.P.2    Young, G.A.3
  • 15
    • 19944430945 scopus 로고    scopus 로고
    • Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995)
    • Cassileth P.A., Lee S.J., Litzow M.R., et al. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma 2005, 46:55-61.
    • (2005) Leuk Lymphoma , vol.46 , pp. 55-61
    • Cassileth, P.A.1    Lee, S.J.2    Litzow, M.R.3
  • 16
    • 36749029331 scopus 로고    scopus 로고
    • Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)
    • Petersdorf S.H., Rankin C., Head D.R., et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Am J Hematol 2007, 82:1056-1062.
    • (2007) Am J Hematol , vol.82 , pp. 1056-1062
    • Petersdorf, S.H.1    Rankin, C.2    Head, D.R.3
  • 17
    • 33745003472 scopus 로고    scopus 로고
    • Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and post-remission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
    • Büchner T., Berdel W.E., Schoch C., et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and post-remission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006, 24:2480-2489.
    • (2006) J Clin Oncol , vol.24 , pp. 2480-2489
    • Büchner, T.1    Berdel, W.E.2    Schoch, C.3
  • 18
    • 79952808421 scopus 로고    scopus 로고
    • Cytarabine dose for acute myeloid leukemia
    • Löwenberg B., Pabst T., Vellenga E., et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011, 364:1027-1036.
    • (2011) N Engl J Med , vol.364 , pp. 1027-1036
    • Löwenberg, B.1    Pabst, T.2    Vellenga, E.3
  • 19
    • 77957715843 scopus 로고    scopus 로고
    • Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience
    • Medeiros B.C., Othus M., Fang M., et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010, 116:2224-2228.
    • (2010) Blood , vol.116 , pp. 2224-2228
    • Medeiros, B.C.1    Othus, M.2    Fang, M.3
  • 20
    • 0030895252 scopus 로고    scopus 로고
    • Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10)
    • Hann I.M., Stevens R.F., Goldstone A.H., et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood 1997, 89:2311-2318.
    • (1997) Blood , vol.89 , pp. 2311-2318
    • Hann, I.M.1    Stevens, R.F.2    Goldstone, A.H.3
  • 21
    • 0035895052 scopus 로고    scopus 로고
    • Comparison of idarubicin + ara-C, fludarabine + araC-, and Topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
    • Estey E.H., Thall P.F., Cortes J.E., et al. Comparison of idarubicin + ara-C, fludarabine + araC-, and Topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001, 98:3575-3583.
    • (2001) Blood , vol.98 , pp. 3575-3583
    • Estey, E.H.1    Thall, P.F.2    Cortes, J.E.3
  • 22
    • 11144358126 scopus 로고    scopus 로고
    • The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
    • Ossenkoppele G.J., Graveland W.J., Sonneveld P., et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004, 103:2908-2913.
    • (2004) Blood , vol.103 , pp. 2908-2913
    • Ossenkoppele, G.J.1    Graveland, W.J.2    Sonneveld, P.3
  • 23
    • 33745113550 scopus 로고    scopus 로고
    • Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
    • Milligan D.W., Wheatley K., Littlewood T., et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006, 107:4614-4622.
    • (2006) Blood , vol.107 , pp. 4614-4622
    • Milligan, D.W.1    Wheatley, K.2    Littlewood, T.3
  • 24
    • 0035760302 scopus 로고    scopus 로고
    • Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
    • List A.F., Kopecky K.J., Willman C.L., et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001, 98:3212-3220.
    • (2001) Blood , vol.98 , pp. 3212-3220
    • List, A.F.1    Kopecky, K.J.2    Willman, C.L.3
  • 25
    • 77956578835 scopus 로고    scopus 로고
    • P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
    • Kolitz J.E., George S.L., Marcucci G., et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010, 116:1413-1421.
    • (2010) Blood , vol.116 , pp. 1413-1421
    • Kolitz, J.E.1    George, S.L.2    Marcucci, G.3
  • 26
    • 0031811585 scopus 로고    scopus 로고
    • Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections
    • Rowe J.M. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin Infect Dis 1998, 26:1290-1294.
    • (1998) Clin Infect Dis , vol.26 , pp. 1290-1294
    • Rowe, J.M.1
  • 27
    • 22044454414 scopus 로고    scopus 로고
    • Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML13, a randomized phase 3 study of the European Organization for Research and Treatment of Cancer and Grippo Italiano Malattie Ematologiche dell Advito (EORTG/GIMEMA) Leukemia groups
    • Amadori S., Suciu S., Jehn U., et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML13, a randomized phase 3 study of the European Organization for Research and Treatment of Cancer and Grippo Italiano Malattie Ematologiche dell Advito (EORTG/GIMEMA) Leukemia groups. Blood 2005, 106:27-34.
    • (2005) Blood , vol.106 , pp. 27-34
    • Amadori, S.1    Suciu, S.2    Jehn, U.3
  • 28
    • 0042967809 scopus 로고    scopus 로고
    • Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
    • Löwenberg B., van Putten W., Theobald M., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
    • (2003) N Engl J Med , vol.349 , pp. 743-752
    • Löwenberg, B.1    van Putten, W.2    Theobald, M.3
  • 29
    • 33847202969 scopus 로고    scopus 로고
    • Effect of priming with granulocyte-macrophage colony stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group
    • Thomas X., Raffoux E., de Botton S., et al. Effect of priming with granulocyte-macrophage colony stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007, 21:453-461.
    • (2007) Leukemia , vol.21 , pp. 453-461
    • Thomas, X.1    Raffoux, E.2    de Botton, S.3
  • 30
    • 2442458874 scopus 로고    scopus 로고
    • Priming with granulocyte colony stimulating factor - relation to high-dose cytarabine in acute myeloid leukemia [comment]
    • Büchner T., Berdel W.E., Hiddemann W. Priming with granulocyte colony stimulating factor - relation to high-dose cytarabine in acute myeloid leukemia [comment]. N Engl J Med 2004, 350:2215-2216.
    • (2004) N Engl J Med , vol.350 , pp. 2215-2216
    • Büchner, T.1    Berdel, W.E.2    Hiddemann, W.3
  • 31
    • 25144485908 scopus 로고    scopus 로고
    • Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
    • Larson R.A., Sievers E.L., Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104:1442-1452.
    • (2005) Cancer , vol.104 , pp. 1442-1452
    • Larson, R.A.1    Sievers, E.L.2    Stadtmauer, E.A.3
  • 32
    • 77957711298 scopus 로고    scopus 로고
    • Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia
    • Petersdorf S., Kopecky K., Stuart R.K., et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood (ASH Ann Meeting Abstracts) 2009, 114:790.
    • (2009) Blood (ASH Ann Meeting Abstracts) , vol.114 , pp. 790
    • Petersdorf, S.1    Kopecky, K.2    Stuart, R.K.3
  • 33
    • 79952099282 scopus 로고    scopus 로고
    • Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
    • Burnett A.K., Hills R.K., Milligan D., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011, 29:369-377.
    • (2011) J Clin Oncol , vol.29 , pp. 369-377
    • Burnett, A.K.1    Hills, R.K.2    Milligan, D.3
  • 34
    • 0027941369 scopus 로고
    • Intensive post-remission chemotherapy in adults with acute myeloid leukemia
    • Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994, 331:896-903.
    • (1994) N Engl J Med , vol.331 , pp. 896-903
    • Mayer, R.J.1    Davis, R.B.2    Schiffer, C.A.3
  • 35
    • 17544388046 scopus 로고    scopus 로고
    • Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
    • Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179.
    • (1998) Cancer Res , vol.58 , pp. 4173-4179
    • Bloomfield, C.D.1    Lawrence, D.2    Byrd, J.C.3
  • 36
    • 0032793987 scopus 로고    scopus 로고
    • Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
    • Byrd J.C., Dodge R.K., Carroll A., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999, 17:3767-3775.
    • (1999) J Clin Oncol , vol.17 , pp. 3767-3775
    • Byrd, J.C.1    Dodge, R.K.2    Carroll, A.3
  • 37
    • 1842614240 scopus 로고    scopus 로고
    • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
    • Byrd J.C., Ruppert A.S., Mrózek K., et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004, 22:1087-1094.
    • (2004) J Clin Oncol , vol.22 , pp. 1087-1094
    • Byrd, J.C.1    Ruppert, A.S.2    Mrózek, K.3
  • 38
    • 0032188805 scopus 로고    scopus 로고
    • The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial
    • Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998, 92:2322-2333.
    • (1998) Blood , vol.92 , pp. 2322-2333
    • Grimwade, D.1    Walker, H.2    Oliver, F.3
  • 39
    • 0032480930 scopus 로고    scopus 로고
    • Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
    • Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649-1656.
    • (1998) N Engl J Med , vol.339 , pp. 1649-1656
    • Cassileth, P.A.1    Harrington, D.P.2    Appelbaum, F.R.3
  • 40
    • 0034672269 scopus 로고    scopus 로고
    • Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
    • Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96:4075-4083.
    • (2000) Blood , vol.96 , pp. 4075-4083
    • Slovak, M.L.1    Kopecky, K.J.2    Cassileth, P.A.3
  • 41
    • 0042527742 scopus 로고    scopus 로고
    • Risk-adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial
    • Schlenk R.F., Benner A., Hartmann F., et al. Risk-adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial. Leukemia 2003, 17:1521-1528.
    • (2003) Leukemia , vol.17 , pp. 1521-1528
    • Schlenk, R.F.1    Benner, A.2    Hartmann, F.3
  • 42
    • 33748747555 scopus 로고    scopus 로고
    • The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
    • Appelbaum F.R., Kopecky K.J., Tallman M.S., et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006, 135:165-173.
    • (2006) Br J Haematol , vol.135 , pp. 165-173
    • Appelbaum, F.R.1    Kopecky, K.J.2    Tallman, M.S.3
  • 43
    • 34247325560 scopus 로고    scopus 로고
    • Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: benefits for whom?
    • Cornelissen J.J., van Putten W.L.J., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: benefits for whom?. Blood 2007, 109:3658-3666.
    • (2007) Blood , vol.109 , pp. 3658-3666
    • Cornelissen, J.J.1    van Putten, W.L.J.2    Verdonck, L.F.3
  • 44
    • 16844374525 scopus 로고    scopus 로고
    • Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis
    • Yanada M., Matsuo K., Emi N., et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005, 103:1652-1658.
    • (2005) Cancer , vol.103 , pp. 1652-1658
    • Yanada, M.1    Matsuo, K.2    Emi, N.3
  • 45
    • 67049164836 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
    • Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
    • (2009) JAMA , vol.301 , pp. 2349-2361
    • Koreth, J.1    Schlenk, R.2    Kopecky, K.J.3
  • 46
    • 4644288302 scopus 로고    scopus 로고
    • Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup
    • Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 15:3741-3750.
    • (2004) J Clin Oncol , vol.15 , pp. 3741-3750
    • Schlenk, R.F.1    Benner, A.2    Krauter, J.3
  • 47
    • 0037093053 scopus 로고    scopus 로고
    • A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup
    • Nguyen S., Leblanc T., Fenaux P., et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002, 99:3517-3523.
    • (2002) Blood , vol.99 , pp. 3517-3523
    • Nguyen, S.1    Leblanc, T.2    Fenaux, P.3
  • 48
    • 0038156371 scopus 로고    scopus 로고
    • Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup
    • Delaunay J., Vey N., Leblanc T., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003, 102:462-469.
    • (2003) Blood , vol.102 , pp. 462-469
    • Delaunay, J.1    Vey, N.2    Leblanc, T.3
  • 49
    • 33748467435 scopus 로고    scopus 로고
    • Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study
    • Paschka P., Marcucci G., Ruppert A., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol 2006, 24:3904-3911.
    • (2006) J Clin Oncol , vol.24 , pp. 3904-3911
    • Paschka, P.1    Marcucci, G.2    Ruppert, A.3
  • 50
    • 42949142189 scopus 로고    scopus 로고
    • Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
    • Schlenk R., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
    • (2008) N Engl J Med , vol.358 , pp. 1909-1918
    • Schlenk, R.1    Döhner, K.2    Krauter, J.3
  • 51
    • 77955907891 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutations are frequent genetics alternations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM 1 mutation without FLT3 internal tandem duplication
    • Paschka P., Schlenk R.F., Gaidzik, et al. IDH1 and IDH2 mutations are frequent genetics alternations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM 1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
    • (2010) J Clin Oncol , vol.28 , pp. 3636-3643
    • Paschka, P.1    Schlenk, R.F.2    Gaidzik3
  • 52
    • 79960534917 scopus 로고    scopus 로고
    • The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
    • Green C.L., Evans C.M., Zhao L., et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118:409-412.
    • (2011) Blood , vol.118 , pp. 409-412
    • Green, C.L.1    Evans, C.M.2    Zhao, L.3
  • 53
    • 77954921625 scopus 로고    scopus 로고
    • Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations
    • Green C.L., Koo K.K., Hills R.K., et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28:2739-2747.
    • (2010) J Clin Oncol , vol.28 , pp. 2739-2747
    • Green, C.L.1    Koo, K.K.2    Hills, R.K.3
  • 54
    • 0025100777 scopus 로고
    • Graft-versus- leukemia reactions after bone marrow transplantation
    • Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus- leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
    • (1990) Blood , vol.75 , pp. 555-562
    • Horowitz, M.M.1    Gale, R.P.2    Sondel, P.M.3
  • 55
    • 0028889993 scopus 로고
    • Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
    • Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995, 332:217-223.
    • (1995) N Engl J Med , vol.332 , pp. 217-223
    • Zittoun, R.A.1    Mandelli, F.2    Willemze, R.3
  • 56
    • 0036036741 scopus 로고    scopus 로고
    • The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at different risk of relapse: results of the UK MRC 10 trial
    • Burnett A.K., Wheatley K., Goldstone A.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at different risk of relapse: results of the UK MRC 10 trial. Br J Haematol 2002, 118:385-400.
    • (2002) Br J Haematol , vol.118 , pp. 385-400
    • Burnett, A.K.1    Wheatley, K.2    Goldstone, A.H.3
  • 57
    • 67651065502 scopus 로고    scopus 로고
    • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
    • Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
    • (2009) Blood , vol.114 , pp. 144-147
    • Abdel-Wahab, O.1    Mullally, A.2    Hedvat, C.3
  • 58
    • 54349092877 scopus 로고    scopus 로고
    • Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype
    • Breems D.A., Van Putten L.J., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26:4791-4797.
    • (2008) J Clin Oncol , vol.26 , pp. 4791-4797
    • Breems, D.A.1    Van Putten, L.J.2    De Greef, G.E.3
  • 59
    • 64849088683 scopus 로고    scopus 로고
    • Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission
    • Basara N., Schulze A., Wedding U., et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009, 23:635-640.
    • (2009) Leukemia , vol.23 , pp. 635-640
    • Basara, N.1    Schulze, A.2    Wedding, U.3
  • 60
    • 33846585857 scopus 로고    scopus 로고
    • Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML
    • Krauter J., Heil G., Hoelzer D., et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood (Ann Meeting Abstracts) 2005, 106:172.
    • (2005) Blood (Ann Meeting Abstracts) , vol.106 , pp. 172
    • Krauter, J.1    Heil, G.2    Hoelzer, D.3
  • 61
    • 81255161076 scopus 로고    scopus 로고
    • Outcome following hematopoietic cell transplantation for patients with AML-CR1: comparison between matched-sibling and unrelated allografts
    • Pagel J., Gooley T., Petersdorf E., et al. Outcome following hematopoietic cell transplantation for patients with AML-CR1: comparison between matched-sibling and unrelated allografts. Blood (Ann Meeting Abstracts) 2007, 110:330.
    • (2007) Blood (Ann Meeting Abstracts) , vol.110 , pp. 330
    • Pagel, J.1    Gooley, T.2    Petersdorf, E.3
  • 62
    • 34347391058 scopus 로고    scopus 로고
    • Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
    • Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110:409-417.
    • (2007) Blood , vol.110 , pp. 409-417
    • Tallman, M.S.1    Dewald, G.W.2    Gandham, S.3
  • 63
    • 78649462137 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood
    • Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4694-4699.
    • (2010) Blood , vol.116 , pp. 4694-4699
    • Brunstein, C.G.1    Gutman, J.A.2    Weisdorf, D.J.3
  • 64
    • 55749091291 scopus 로고    scopus 로고
    • A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation
    • Ciceri F., Labopin M., Aversa F., et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112:3574-3581.
    • (2008) Blood , vol.112 , pp. 3574-3581
    • Ciceri, F.1    Labopin, M.2    Aversa, F.3
  • 65
    • 0032492441 scopus 로고    scopus 로고
    • Randomised comparison of addition of autologous bone-arrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
    • Burnett A.K., Goldstone A.H., Stevens R.F., et al. Randomised comparison of addition of autologous bone-arrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998, 351:700-708.
    • (1998) Lancet , vol.351 , pp. 700-708
    • Burnett, A.K.1    Goldstone, A.H.2    Stevens, R.F.3
  • 66
    • 9844244021 scopus 로고    scopus 로고
    • Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia
    • Harrousseau J.L., Chan J.Y., Pignon B., et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997, 90:2978-2986.
    • (1997) Blood , vol.90 , pp. 2978-2986
    • Harrousseau, J.L.1    Chan, J.Y.2    Pignon, B.3
  • 67
    • 79956369016 scopus 로고    scopus 로고
    • Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
    • Fernandez H.F., Sun Z., Litzow M.R., et al. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood 2011, 177:5306-5313.
    • (2011) Blood , vol.177 , pp. 5306-5313
    • Fernandez, H.F.1    Sun, Z.2    Litzow, M.R.3
  • 68
    • 0026668478 scopus 로고
    • Varying intensity of post-remission therapy in acute myeloid leukemia
    • Cassileth P., Lynch E., Hines J., et al. Varying intensity of post-remission therapy in acute myeloid leukemia. Blood 1992, 79:1924-1930.
    • (1992) Blood , vol.79 , pp. 1924-1930
    • Cassileth, P.1    Lynch, E.2    Hines, J.3
  • 69
    • 1542753653 scopus 로고    scopus 로고
    • 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML). A randomized trial of the German AML Cooperative Group
    • Büchner T., Hiddemann W., Berdei W., et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML). A randomized trial of the German AML Cooperative Group. J Clin Oncol 2003, 21:4496-4504.
    • (2003) J Clin Oncol , vol.21 , pp. 4496-4504
    • Büchner, T.1    Hiddemann, W.2    Berdei, W.3
  • 70
    • 0028926870 scopus 로고
    • A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML). A Southwest Oncology Group Study
    • Hewlett J., Kopecky K., Head D., et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML). A Southwest Oncology Group Study. Leukemia 1995, 9:562-569.
    • (1995) Leukemia , vol.9 , pp. 562-569
    • Hewlett, J.1    Kopecky, K.2    Head, D.3
  • 71
    • 0034114681 scopus 로고    scopus 로고
    • Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission
    • Blaise D., Attal M., Reiffers J., et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000, 11:91-98.
    • (2000) Eur Cytokine Netw , vol.11 , pp. 91-98
    • Blaise, D.1    Attal, M.2    Reiffers, J.3
  • 72
    • 33745723974 scopus 로고    scopus 로고
    • Outcomes in CCG-2961, a Children's Cancer Group phase III trial for untreated acute myeloid leukemia (AML)
    • Lange B.J., Smith F.O., Dinndorf P.A., et al. Outcomes in CCG-2961, a Children's Cancer Group phase III trial for untreated acute myeloid leukemia (AML). Blood (ANN Meeting Abstracts) 2005, 106:169.
    • (2005) Blood (ANN Meeting Abstracts) , vol.106 , pp. 169
    • Lange, B.J.1    Smith, F.O.2    Dinndorf, P.A.3
  • 73
    • 33745714215 scopus 로고    scopus 로고
    • Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
    • Brune M., Castaigne S., Catalano J., et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006, 108:88-96.
    • (2006) Blood , vol.108 , pp. 88-96
    • Brune, M.1    Castaigne, S.2    Catalano, J.3
  • 74
    • 4644289323 scopus 로고    scopus 로고
    • Induction of WT1 (Wilms' tumor gene)-specific cytoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
    • Oka Y., Tsuboi A., Taguchi T., et al. Induction of WT1 (Wilms' tumor gene)-specific cytoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004, 101:13885-13890.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 13885-13890
    • Oka, Y.1    Tsuboi, A.2    Taguchi, T.3
  • 75
    • 69249220181 scopus 로고    scopus 로고
    • A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
    • Keilholz U., Letsch A., Busse A., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
    • (2009) Blood , vol.113 , pp. 6541-6548
    • Keilholz, U.1    Letsch, A.2    Busse, A.3
  • 76
    • 77955481538 scopus 로고    scopus 로고
    • Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
    • Maslak P.G., Dao T., Krug L.M., et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010, (116):171-179.
    • (2010) Blood , Issue.116 , pp. 171-179
    • Maslak, P.G.1    Dao, T.2    Krug, L.M.3
  • 77
    • 29844437061 scopus 로고    scopus 로고
    • Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia
    • Qazibash M.H., Wieder E., Rios R., et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood (Ann Meeting Abstracts) 2004, 104:259.
    • (2004) Blood (Ann Meeting Abstracts) , vol.104 , pp. 259
    • Qazibash, M.H.1    Wieder, E.2    Rios, R.3
  • 78
    • 77956384935 scopus 로고    scopus 로고
    • Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
    • Van Tendeloo V.F., Van de Velde A., Van Driessche A., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010, 107:13824-13829.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 13824-13829
    • Van Tendeloo, V.F.1    Van de Velde, A.2    Van Driessche, A.3
  • 79
    • 33646404606 scopus 로고    scopus 로고
    • Age and acute myeloid leukemia
    • Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2005, 107:3481-3485.
    • (2005) Blood , vol.107 , pp. 3481-3485
    • Appelbaum, F.R.1    Gundacker, H.2    Head, D.R.3
  • 80
    • 0037158110 scopus 로고    scopus 로고
    • The outcomes and costs of acute myeloid leukemia among the elderly
    • Menzin J., Lang K., Earle C.C., et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603.
    • (2002) Arch Intern Med , vol.162 , pp. 1597-1603
    • Menzin, J.1    Lang, K.2    Earle, C.C.3
  • 81
    • 66149148673 scopus 로고    scopus 로고
    • Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
    • Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
    • (2009) Blood , vol.113 , pp. 4179-4187
    • Juliusson, G.1    Antunovic, P.2    Derolf, A.3
  • 82
    • 0034773058 scopus 로고    scopus 로고
    • Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia
    • Wahlin A., Markevärn B., Golovleva I., et al. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haemat 2001, 115:25-33.
    • (2001) Br J Haemat , vol.115 , pp. 25-33
    • Wahlin, A.1    Markevärn, B.2    Golovleva, I.3
  • 83
    • 84859884962 scopus 로고    scopus 로고
    • A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia
    • [Epub ahead of print]
    • Valcárcel D., Montesinos P., Sánchenz-Ortega I., et al. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer 2011, [Epub ahead of print].
    • (2011) Cancer
    • Valcárcel, D.1    Montesinos, P.2    Sánchenz-Ortega, I.3
  • 84
    • 33644521267 scopus 로고    scopus 로고
    • Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome
    • Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
    • (2006) Cancer , vol.106 , pp. 1090-1098
    • Kantarjian, H.1    O'Brien, S.2    Cortes, J.3
  • 85
    • 78649486856 scopus 로고    scopus 로고
    • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
    • Kantarjian H., Ravandi F., O'Brien S., et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010, 118:4422-4429.
    • (2010) Blood , vol.118 , pp. 4422-4429
    • Kantarjian, H.1    Ravandi, F.2    O'Brien, S.3
  • 86
    • 9144238671 scopus 로고    scopus 로고
    • A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
    • Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479-485.
    • (2004) Blood , vol.103 , pp. 479-485
    • Rowe, J.M.1    Neuberg, D.2    Friedenberg, W.3
  • 87
    • 70349451999 scopus 로고    scopus 로고
    • High-dose daunorubicin in older patients with acute myeloid leukemia
    • Löwenberg B., Ossenkoppele G.J., Van Putten W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
    • (2009) N Engl J Med , vol.361 , pp. 1235-1248
    • Löwenberg, B.1    Ossenkoppele, G.J.2    Van Putten, W.3
  • 88
    • 78549238612 scopus 로고    scopus 로고
    • Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
    • Cripe L.D., Uno H., Paietta E.M., et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010, 116:4077-4085.
    • (2010) Blood , vol.116 , pp. 4077-4085
    • Cripe, L.D.1    Uno, H.2    Paietta, E.M.3
  • 89
    • 0029033064 scopus 로고
    • Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
    • Stone R.M., Berg D.T., George S.L., et al. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995, 332:1671-1677.
    • (1995) N Engl J Med , vol.332 , pp. 1671-1677
    • Stone, R.M.1    Berg, D.T.2    George, S.L.3
  • 90
    • 0029015209 scopus 로고
    • A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)
    • Rowe J.M., Andersen J.W., Mazza J.J., et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995, 86:457-462.
    • (1995) Blood , vol.86 , pp. 457-462
    • Rowe, J.M.1    Andersen, J.W.2    Mazza, J.J.3
  • 91
    • 0029068452 scopus 로고
    • A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
    • Dombret H., Chastang C., Fenaux P., et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995, 332:1678-1783.
    • (1995) N Engl J Med , vol.332 , pp. 1678-1783
    • Dombret, H.1    Chastang, C.2    Fenaux, P.3
  • 92
    • 78650426052 scopus 로고    scopus 로고
    • BAALC and ERG expression levels are associated with outcome and distinct gene- and microRNA-expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    • Schwind S., Marcucci G., Maharry K., et al. BAALC and ERG expression levels are associated with outcome and distinct gene- and microRNA-expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010, 116:5660-5669.
    • (2010) Blood , vol.116 , pp. 5660-5669
    • Schwind, S.1    Marcucci, G.2    Maharry, K.3
  • 93
    • 33646784711 scopus 로고    scopus 로고
    • The role of post-remission chemotherapy for older patients with acute myelogenous leukemia
    • Abou-Jawde R.M., Sobecks R., Pohlman B., et al. The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma 2006, 47:689-695.
    • (2006) Leuk Lymphoma , vol.47 , pp. 689-695
    • Abou-Jawde, R.M.1    Sobecks, R.2    Pohlman, B.3
  • 94
    • 0035469856 scopus 로고    scopus 로고
    • Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
    • Goldstone A.H., Burnett A.K., Wheatley K., et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1302-1311.
    • (2001) Blood , vol.98 , pp. 1302-1311
    • Goldstone, A.H.1    Burnett, A.K.2    Wheatley, K.3
  • 95
    • 34250157761 scopus 로고    scopus 로고
    • Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multi-center randomized Acute Leukemia French Associate (ALFA) 9803 trial
    • Gardin C., Turturee P., Fagot T., et al. Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multi-center randomized Acute Leukemia French Associate (ALFA) 9803 trial. Blood 2007, 109:5129-5135.
    • (2007) Blood , vol.109 , pp. 5129-5135
    • Gardin, C.1    Turturee, P.2    Fagot, T.3
  • 96
    • 33646472600 scopus 로고    scopus 로고
    • Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial
    • [letter]
    • Schlenk R.F., Fröhling S., Martmann F., et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial. Leukemia 2006, 20:748-750. [letter].
    • (2006) Leukemia , vol.20 , pp. 748-750
    • Schlenk, R.F.1    Fröhling, S.2    Martmann, F.3
  • 97
    • 33846924515 scopus 로고    scopus 로고
    • Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HCT) in elderly patients with acute myeloid leukemia (AML and high-risk myelodysplastic syndrome (MDS)
    • Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HCT) in elderly patients with acute myeloid leukemia (AML and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
    • (2007) Blood , vol.109 , pp. 1395-1400
    • Estey, E.1    de Lima, M.2    Tibes, R.3
  • 98
    • 0035254219 scopus 로고    scopus 로고
    • Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    • Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97:631-637.
    • (2001) Blood , vol.97 , pp. 631-637
    • Giralt, S.1    Thall, P.F.2    Khouri, I.3
  • 99
    • 19944429335 scopus 로고    scopus 로고
    • Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning
    • Shimoni A., Kröger N., Zabelina T., et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005, 19:7-12.
    • (2005) Leukemia , vol.19 , pp. 7-12
    • Shimoni, A.1    Kröger, N.2    Zabelina, T.3
  • 100
    • 33644833398 scopus 로고    scopus 로고
    • Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
    • Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24:444-453.
    • (2006) J Clin Oncol , vol.24 , pp. 444-453
    • Hegenbart, U.1    Niederwieser, D.2    Sandmaier, B.M.3
  • 101
    • 55949099856 scopus 로고    scopus 로고
    • Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the Cooperative German Transplant Study Group
    • Schetelig J., Bornhäuser M., Schmid C., et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the Cooperative German Transplant Study Group. J Clin Oncol 2008, 26:5183-5191.
    • (2008) J Clin Oncol , vol.26 , pp. 5183-5191
    • Schetelig, J.1    Bornhäuser, M.2    Schmid, C.3
  • 102
    • 33947205565 scopus 로고    scopus 로고
    • A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    • Burnett A.K., Milligan D., Prentice A.G., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
    • (2007) Cancer , vol.109 , pp. 1114-1124
    • Burnett, A.K.1    Milligan, D.2    Prentice, A.G.3
  • 103
    • 33847001315 scopus 로고    scopus 로고
    • A phase 2 study of farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    • Lancet J.E., Gojo I., Gotlib J., et al. A phase 2 study of farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007, 109:1387-1394.
    • (2007) Blood , vol.109 , pp. 1387-1394
    • Lancet, J.E.1    Gojo, I.2    Gotlib, J.3
  • 104
    • 69849092737 scopus 로고    scopus 로고
    • A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
    • Harousseau J.-L., Martinelli G., Jedrzejczak W.W., et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009, 114:1166-1173.
    • (2009) Blood , vol.114 , pp. 1166-1173
    • Harousseau, J.-L.1    Martinelli, G.2    Jedrzejczak, W.W.3
  • 105
    • 77649194028 scopus 로고    scopus 로고
    • Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia
    • Schiller G.J., O'Brien S.M., Pigneux A., et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol 2009, 28:815-821.
    • (2009) J Clin Oncol , vol.28 , pp. 815-821
    • Schiller, G.J.1    O'Brien, S.M.2    Pigneux, A.3
  • 106
    • 77449159668 scopus 로고    scopus 로고
    • Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
    • Kantarjian H.M., Erba H.P., Claxton D., et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010, 28:549-555.
    • (2010) J Clin Oncol , vol.28 , pp. 549-555
    • Kantarjian, H.M.1    Erba, H.P.2    Claxton, D.3
  • 107
    • 77952491723 scopus 로고    scopus 로고
    • European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy
    • Burnett A.K., Russell N.H., Kell J., et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010, 28:2389-2395.
    • (2010) J Clin Oncol , vol.28 , pp. 2389-2395
    • Burnett, A.K.1    Russell, N.H.2    Kell, J.3
  • 108
    • 52649154001 scopus 로고    scopus 로고
    • A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    • Faderl S., Ravandi F., Huang X., et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008, 112:1638-1645.
    • (2008) Blood , vol.112 , pp. 1638-1645
    • Faderl, S.1    Ravandi, F.2    Huang, X.3
  • 109
    • 33745586575 scopus 로고    scopus 로고
    • Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    • Faderl S., Verstovsek S., Cortes J., et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006, 108:45-51.
    • (2006) Blood , vol.108 , pp. 45-51
    • Faderl, S.1    Verstovsek, S.2    Cortes, J.3
  • 110
    • 77449149373 scopus 로고    scopus 로고
    • Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
    • Fenaux P., Mufti G.J., Hellström-Lindberg E., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2009, 28:562-569.
    • (2009) J Clin Oncol , vol.28 , pp. 562-569
    • Fenaux, P.1    Mufti, G.J.2    Hellström-Lindberg, E.3
  • 111
    • 77449149374 scopus 로고    scopus 로고
    • Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    • Cashen A.F., Schiller G.J., O'Donnell M.R., et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2009, 28:556-561.
    • (2009) J Clin Oncol , vol.28 , pp. 556-561
    • Cashen, A.F.1    Schiller, G.J.2    O'Donnell, M.R.3
  • 112
    • 77952140672 scopus 로고    scopus 로고
    • Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    • Blum W., Garzon R., Klisovic R.B., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010, 107:7475-7478.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 7475-7478
    • Blum, W.1    Garzon, R.2    Klisovic, R.B.3
  • 113
    • 81255161073 scopus 로고    scopus 로고
    • Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML
    • Thomas X.G., Dmoszynska A., Wierzbowska A., et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J Clin Oncol ASCO Ann Meeting Proc 2011, 29:6504.
    • (2011) J Clin Oncol ASCO Ann Meeting Proc , vol.29 , pp. 6504
    • Thomas, X.G.1    Dmoszynska, A.2    Wierzbowska, A.3
  • 114
    • 79951495012 scopus 로고    scopus 로고
    • A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    • Fehniger T.A., Uy G.L., Trinkaus K., et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011, 117:1828-1833.
    • (2011) Blood , vol.117 , pp. 1828-1833
    • Fehniger, T.A.1    Uy, G.L.2    Trinkaus, K.3
  • 115
    • 79960687125 scopus 로고    scopus 로고
    • A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: SWOG Study S0605
    • Sekeres M.A., Gundacker H., Lancet J., et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: SWOG Study S0605. Blood 2011, 118:523-528.
    • (2011) Blood , vol.118 , pp. 523-528
    • Sekeres, M.A.1    Gundacker, H.2    Lancet, J.3
  • 116
    • 22044442973 scopus 로고    scopus 로고
    • Tyrosine kinases as targets for cancer therapy
    • Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
    • (2005) N Engl J Med , vol.353 , pp. 172-187
    • Krause, D.S.1    Van Etten, R.A.2
  • 117
    • 0036595143 scopus 로고    scopus 로고
    • Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
    • Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1:433-443.
    • (2002) Cancer Cell , vol.1 , pp. 433-443
    • Weisberg, E.1    Boulton, C.2    Kelly, L.M.3
  • 118
    • 0036624916 scopus 로고    scopus 로고
    • A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
    • Levis M., Allebach J., Tse K.F., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99:3885-3891.
    • (2002) Blood , vol.99 , pp. 3885-3891
    • Levis, M.1    Allebach, J.2    Tse, K.F.3
  • 119
    • 33845240584 scopus 로고    scopus 로고
    • Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
    • DeAngelo D.J., Stone R.M., Heaney M.A., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108:3674-3681.
    • (2006) Blood , vol.108 , pp. 3674-3681
    • DeAngelo, D.J.1    Stone, R.M.2    Heaney, M.A.3
  • 120
    • 0038204144 scopus 로고    scopus 로고
    • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    • O'Farrell A.-M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
    • (2003) Blood , vol.101 , pp. 3597-3605
    • O'Farrell, A.-M.1    Abrams, T.J.2    Yuen, H.A.3
  • 121
    • 33847195060 scopus 로고    scopus 로고
    • Antitumor activity of sorafenib in FLT3-driven leukemic cells
    • Auclair D., Miller D., Yatsula V., et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007, 21:439-445.
    • (2007) Leukemia , vol.21 , pp. 439-445
    • Auclair, D.1    Miller, D.2    Yatsula, V.3
  • 122
    • 19944427559 scopus 로고    scopus 로고
    • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
    • Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105:54-60.
    • (2005) Blood , vol.105 , pp. 54-60
    • Stone, R.M.1    DeAngelo, D.J.2    Klimek, V.3
  • 123
    • 1842420032 scopus 로고    scopus 로고
    • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    • Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-3676.
    • (2004) Blood , vol.103 , pp. 3669-3676
    • Smith, B.D.1    Levis, M.2    Beran, M.3
  • 124
    • 79953124734 scopus 로고    scopus 로고
    • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
    • Levis M., Ravandi F., Wang E.S., et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, 117:3294-3301.
    • (2011) Blood , vol.117 , pp. 3294-3301
    • Levis, M.1    Ravandi, F.2    Wang, E.S.3
  • 125
    • 77950423964 scopus 로고    scopus 로고
    • Phase Ib study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3
    • Stone R.M., Fischer T., Paquette R., et al. Phase Ib study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. Blood (ASH Annual Meeting Abstracts) 2009, 114:634.
    • (2009) Blood (ASH Annual Meeting Abstracts) , vol.114 , pp. 634
    • Stone, R.M.1    Fischer, T.2    Paquette, R.3
  • 126
    • 77950421846 scopus 로고    scopus 로고
    • AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study
    • Cortes J., Foran J., Ghirdaladze D., et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. Blood (ASH Annual Meeting Abstracts) 2009, 114:636.
    • (2009) Blood (ASH Annual Meeting Abstracts) , vol.114 , pp. 636
    • Cortes, J.1    Foran, J.2    Ghirdaladze, D.3
  • 127
    • 41949125894 scopus 로고    scopus 로고
    • A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    • Raponi M., Lancet J.E., Fan H., et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008, 111:2589-2596.
    • (2008) Blood , vol.111 , pp. 2589-2596
    • Raponi, M.1    Lancet, J.E.2    Fan, H.3
  • 128
    • 81255158147 scopus 로고    scopus 로고
    • Correlation of RASVRP1:APTX expression assay with response to tipifarnib plus etoposide in elderly patients with newly diagnosed AML
    • Vener T.I., Derecho C., Galkin S., et al. Correlation of RASVRP1:APTX expression assay with response to tipifarnib plus etoposide in elderly patients with newly diagnosed AML. J Clin Oncol ASCO Ann Meeting Proc 2011, 29:6534.
    • (2011) J Clin Oncol ASCO Ann Meeting Proc , vol.29 , pp. 6534
    • Vener, T.I.1    Derecho, C.2    Galkin, S.3
  • 129
    • 77954087827 scopus 로고    scopus 로고
    • A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory AML
    • Uy G.L., Rettig M.P., McFarland K., et al. A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory AML. Blood (ASH Annual Meeting Abstracts) 2009, 114:787.
    • (2009) Blood (ASH Annual Meeting Abstracts) , vol.114 , pp. 787
    • Uy, G.L.1    Rettig, M.P.2    McFarland, K.3
  • 130
    • 77953255617 scopus 로고    scopus 로고
    • A randomized phase 2 study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse
    • Kantarjian H.M., Garcia-Manero G., Luger S., et al. A randomized phase 2 study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse. Blood (ASH Ann Meeting Abstracts) 2009, 114:1061.
    • (2009) Blood (ASH Ann Meeting Abstracts) , vol.114 , pp. 1061
    • Kantarjian, H.M.1    Garcia-Manero, G.2    Luger, S.3
  • 131
    • 81255136297 scopus 로고    scopus 로고
    • A phase II multicentre study with elacytarabine as second salvage therapy in patients with AML
    • O'Brien S., Rizzieri D.A., Vey N., et al. A phase II multicentre study with elacytarabine as second salvage therapy in patients with AML. Blood (ASH Ann Meeting Abstract) 2009, 114:1042.
    • (2009) Blood (ASH Ann Meeting Abstract) , vol.114 , pp. 1042
    • O'Brien, S.1    Rizzieri, D.A.2    Vey, N.3
  • 132
    • 79952757852 scopus 로고    scopus 로고
    • First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
    • Feldman E.J., Lancet J.E., Kolitz J.E., et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011, 29:979-985.
    • (2011) J Clin Oncol , vol.29 , pp. 979-985
    • Feldman, E.J.1    Lancet, J.E.2    Kolitz, J.E.3
  • 133
    • 81255127741 scopus 로고    scopus 로고
    • Phase 2B randomized study of CPX-351 vs. cytarabine and daunorubicin (7+3 regimen) in newly diagnosed AML patients aged 60-75
    • Lancet J.E., Cortes J.E., Hogge D.E., et al. Phase 2B randomized study of CPX-351 vs. cytarabine and daunorubicin (7+3 regimen) in newly diagnosed AML patients aged 60-75. Blood (ASH Ann Meeting Abstracts) 2010, 166:655.
    • (2010) Blood (ASH Ann Meeting Abstracts) , vol.166 , pp. 655
    • Lancet, J.E.1    Cortes, J.E.2    Hogge, D.E.3
  • 134
    • 81255158144 scopus 로고    scopus 로고
    • CPX-351 versus cytarabine and daunorubicin therapy in newly diagnosed AML patients age 60-75: safety and efficacy in secondary AML
    • Lancet J.E., Cortes J.E., Kovacosvics T., et al. CPX-351 versus cytarabine and daunorubicin therapy in newly diagnosed AML patients age 60-75: safety and efficacy in secondary AML. J Clin Oncol ASCO Ann Meeting Proc 2011, 29:6519.
    • (2011) J Clin Oncol ASCO Ann Meeting Proc , vol.29 , pp. 6519
    • Lancet, J.E.1    Cortes, J.E.2    Kovacosvics, T.3
  • 135
    • 83555165090 scopus 로고    scopus 로고
    • A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia
    • [Epub ahead of print]
    • Lancet J.E., Ravandi F., Ricklis R.M., et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia 2011, [Epub ahead of print].
    • (2011) Leukemia
    • Lancet, J.E.1    Ravandi, F.2    Ricklis, R.M.3
  • 136
    • 80755126243 scopus 로고    scopus 로고
    • Voreloxin singlxe-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: final results from a phase II study with three schedules
    • Stuart R.K., Ravnadi Kashani F., Cripe L.D., et al. Voreloxin singlxe-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: final results from a phase II study with three schedules. J Clin Oncol ASCO Ann Meeting Proc 2010, 28:6525.
    • (2010) J Clin Oncol ASCO Ann Meeting Proc , vol.28 , pp. 6525
    • Stuart, R.K.1    Ravnadi Kashani, F.2    Cripe, L.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.